![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Lupin Pharmaceuticals Issues Recall for Blood Pressure Meds
Lupin Pharmaceuticals Issues Recall for Blood Pressure Meds
![](https://www.fdanews.com/ext/resources/test/Drug-Images/Lupin-Pharmaceuticals.gif?t=1565046665&width=430)
The FDA announced that Lupin Pharmaceuticals has pulled a lot of its lisinopril 20mg and hydrochlorothiazide 12.5mg tablets, following a complaint regarding a foreign drug tablet.
The agency, which posted the recall of the to its Enforcement Report database, said that a customer discovered a 145mg fenofibrate tablet — used to lower high cholesterol and triglyceride levels — in a 500 count product bottle.
The lot was manufactured at Lupin’s Pithampur, Madhya Pradesh facility, which was hit with a Form 483 following a December 2018 inspection. The investigator noted subpar written procedures for cleaning and maintenance and data integrity concerns.
Upcoming Events
-
21Oct